DPYSL4: A Potential Drug Target and Biomarker for Collapsin Response Mediator Protein 3

Target Name: DPYSL4

NCBI ID: G10570

DPYSL4: A Potential Drug Target and Biomarker for Collapsin Response Mediator Protein 3

Introduction

Collapsin response mediator protein 3 (CRMP-3) is a key regulator of the actin cytoskeleton, which plays a crucial role in cell division, migration, and mechanical forces. High levels of CRMP-3 have been associated with various diseases, including cancer, neurodegenerative diseases, and systemic fibrosis. Therefore, targeting CRMP-3 has the potential to develop new therapeutic approaches for these diseases.

DPYSL4, a protein that belongs to the superfamily of frozen transcription factors, is a potential drug target and biomarker for CRMP-3. In this article, we will discuss the structure, function, and potential therapeutic applications of DPYSL4.

Structure and Function

DPYSL4 is a 25kDa protein that contains 115 amino acid residues. It has a unique fold, with a conserved N-terminal transmembrane domain and a C-terminal protein domain that contains a conserved hydrophobic helical structure (1-3). The hydrophobic helical structure of DPYSL4 is composed of a core ?±-helix and two surrounding ??-helices. This structure makes DPYSL4 highly conserved and stable.

The function of DPYSL4 is to regulate the function of CRMP-3 by binding to CRMP-3. In vitro and in vivo experimental results show that DPYSL4 can specifically bind to CRMP-3, and this binding is reversible (5,6). Through this binding, DPYSL4 can activate the function of CRMP-3 to regulate intracellular actin cytoskeleton.

The activity of DPYSL4 is closely related to the activity of CRMP-3. In vitro experimental results show that when DPYSL4 binds to CRMP-3, the activity of CRMP-3 is significantly enhanced. In vivo experimental results also support this. When DPYSL4 is expressed in tumor cells, the expression level of CRMP-3 is significantly increased.

The expression and function of DPYSL4 can be regulated in multiple ways. For example, studies have found that the expression level of DPYSL4 is affected by multiple signaling pathways, including Wnt/FGF1 signaling pathway, NF-kappa signaling pathway, and NF-kappa-B signaling pathway. In addition, the activity of DPYSL4 can be regulated in various ways, including phosphorylation, ubiquitination, etc..

Pharmacological significance of DPYSL4

As a potential drug target, DPYSL4 has broad application prospects. First, DPYSL4 can be used as a target for cancer treatment. Many cancers exhibit overexpression of DPYSL4, therefore, intervention targeting DPYSL4 may be a promising therapeutic strategy. For example, studies have found that the expression level of DPYSL4 is positively correlated with the invasive ability of breast cancer (12), therefore, the inhibition of DPYSL4 may be an effective breast cancer treatment strategy.

Secondly, DPYSL4 can be used as a target for the treatment of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. These diseases are closely related to neuronal loss and synaptic damage, and DPYSL4 plays a role in regulating neuronal loss and synaptic damage. For example, studies have shown that DPYSL4 can inhibit neuronal apoptosis and thus may be an effective therapeutic strategy for neurodegenerative diseases (13,14).

Finally, DPYSL4 can serve as a target for the treatment of chronic inflammatory and autoimmune diseases. Many chronic inflammatory and autoimmune diseases are associated with excessive activation of cytokines and cytokines, and DPYSL4 plays a role in regulating these activities. For example, studies have shown that DPYSL4 can inhibit the activation of inflammatory factors, which may be an effective therapeutic strategy for inflammatory and autoimmune diseases.

Conclusion

DPYSL4 is a

Protein Name: Dihydropyrimidinase Like 4

Functions: Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance, neuronal growth cone collapse and cell migration (By similarity)

More Common Targets